About: Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies
Creator	Bozinovski, Steven Selemidis, Stavros Vlahos, Ross Chan, Stanley
Source	Elsevier; Medline; PMC
abstract	Chronic obstructive pulmonary disease (COPD) is a major incurable global health burden and is currently the 4th largest cause of death in the world. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities (e.g. skeletal muscle wasting, ischemic heart disease, cognitive dysfunction) and infective viral and bacterial acute exacerbations (AECOPD). Current pharmacological treatments for COPD are relatively ineffective and the development of effective therapies has been severely hampered by the lack of understanding of the mechanisms and mediators underlying COPD. Since comorbidities have a tremendous impact on the prognosis and severity of COPD, the 2015 American Thoracic Society/European Respiratory Society (ATS/ERS) Research Statement on COPD urgently called for studies to elucidate the pathobiological mechanisms linking COPD to its comorbidities. It is now emerging that up to 50% of COPD patients have metabolic syndrome (MetS) as a comorbidity. It is currently not clear whether metabolic syndrome is an independent co-existing condition or a direct consequence of the progressive lung pathology in COPD patients. As MetS has important clinical implications on COPD outcomes, identification of disease mechanisms linking COPD to MetS is the key to effective therapy. In this comprehensive review, we discuss the potential mechanisms linking MetS to COPD and hence plausible therapeutic strategies to treat this debilitating comorbidity of COPD.
has issue date	2019-02-26(xsd:dateTime)
bibo:doi	10.1016/j.pharmthera.2019.02.013
bibo:pmid	30822464
has license	no-cc
sha1sum (hex)	a0c464060a220478a12604e6ee37141c9ca89d8f
schema:url	https://doi.org/10.1016/j.pharmthera.2019.02.013
resource representing a document's title	Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies
has PubMed Central identifier	PMC7112632
has PubMed identifier	30822464
schema:publication	Pharmacol Ther
resource representing a document's body	covid:a0c464060a220478a12604e6ee37141c9ca89d8f#body_text
is schema:about of	named entity 'THERAPEUTIC' named entity 'strategies' named entity 'therapeutic' named entity 'disease burden' named entity 'mechanisms' named entity 'patients' named entity 'treatments' named entity 'linking' named entity 'American Thoracic Society' named entity 'condition' named entity 'Chronic obstructive pulmonary disease (COPD)' named entity 'COPD' named entity 'metabolic syndrome' named entity 'OUTCOMES' named entity 'VIRAL AND' named entity 'DISCUSS' named entity 'THERAPEUTIC' named entity 'THORACIC' named entity 'TREAT' named entity 'KEY' named entity 'POTENTIAL' named entity 'ITS' named entity 'SEVERITY' named entity 'METABOLIC SYNDROME' named entity 'SKELETAL MUSCLE' named entity 'CURRENT' named entity 'CLINICAL' named entity 'AMERICAN' named entity 'PATHOLOGY' named entity 'SOCIETY' named entity 'SEVERELY' named entity 'UP TO' named entity '2015' named entity 'DEVELOPMENT' named entity 'HAVE' named entity 'MANAGEMENT' named entity 'A MAJOR' named entity 'CAUSE OF DEATH' named entity 'PHARMACOLOGICAL TREATMENTS' named entity 'UNDERLYING' named entity 'STRATEGIES' named entity 'CHRONIC OBSTRUCTIVE PULMONARY DISEASE' named entity 'METABOLIC SYNDROME' named entity 'CLINICAL SIGNIFICANCE' named entity 'THERAPY' named entity 'COMPREHENSIVE REVIEW' named entity 'MECHANISMS' named entity 'IMPACT' named entity 'MUCH' named entity 'COGNITIVE DYSFUNCTION' named entity 'HEALTH CARE' named entity 'UNDERSTANDING' named entity 'IDENTIFICATION' named entity 'LACK' named entity 'COMORBIDITY' named entity 'IS A' named entity 'COPD' named entity 'IMPORTANT' named entity 'METS' named entity 'STRATEGIES' named entity 'PROGNOSIS' named entity 'CURRENTLY' named entity 'ACUTE EXACERBATIONS' named entity 'ASSOCIATED WITH' named entity 'BURDEN' named entity 'CONSEQUENCE OF' named entity 'STATEMENT' named entity 'ISCHEMIC HEART DISEASE' named entity 'BACTERIAL' named entity 'RESEARCH' named entity 'MUSCLE WASTING' named entity 'UNDERLYING' named entity 'PROGRESSIVE' named entity 'CONDITION' named entity 'WORLD' named entity 'INEFFECTIVE' named entity 'PATIENTS' named entity 'RESPIRATORY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software